Drug intelligence / Profile preview

Colitis Suppositories

Development stage: Unknown
Lead developer: Shandong Kangzhonghong Medical Technology Development
Administration: Rectal

Overview

Colitis Suppositories is a pharmaceutical drug in suppository form, developed by Shandong Kangzhonghong Medical Technology Development Co. Ltd. It is currently undergoing a preliminary exploratory phase IIa clinical trial for the treatment of mild-to-moderate active ulcerative colitis. The drug is administered rectally. While the specific mechanism of action is not detailed, it is being compared to Mesalazine Suppositories, which are known for their anti-inflammatory effects in the colon.

Beyond the preview

Go deeper on Colitis Suppositories.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colitis Suppositories.

Explore the full profile